NASDAQ: ZYME · Life Sciences · 7 alerts · CIK 1937653
Share price
$26.45Close, Nov 16
Market cap
$1.83B
Shares outstanding
69.03MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Zymeworks Inc. filings on SEC EDGAR ↗
Zymeworks Inc. reported a significant increase in total revenue to $256.5 million for the third quarter of 2026, primarily driven by $250.0 million in license and milestone revenue. The company achieved a net income of $173.7 million for the quarter, a substantial improvement from the $19.6 million net loss in the prior year period, despite an increase in operating expenses to $78.9 million.
Zymeworks reported Q3 2026 financial results and significantly raised its full-year 2026 revenue guidance to $337M-$351M. The company highlighted the recent FDA approval of Ziihera for first-line GEA, which triggered a $250 million milestone payment from Jazz Pharmaceuticals, and the completion of its acquisition of Theravance Biopharma.
Term
Q3 2026
“We are entering the next phase of Zymeworks growth with a fundamentally stronger and more diversified business. The transformation of Zymeworks is becoming increasingly visible in our financial profile and in the breadth of opportunities available to us.”
Kenneth Galbraith, Chair and Chief Executive Officer of Zymeworks
“These advancements demonstrate the strategy we set out a year ago - to build a durable financial foundation through partnered and commercial assets, while maintaining the ability to create additional value through R&D, acquisitions, partnerships and disciplined capital allocation.”
Kenneth Galbraith, Chair and Chief Executive Officer of Zymeworks